Drug Resistance in Pneumonia (DRIP) Score

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
drip score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–3
  • High Risk4–14
Direct Clinical Answer

The Drug Resistance in Pneumonia (DRIP) Score calculates predicting risk for community-acquired pneumonia due to drug-resistant pathogens (CAP-DRP). Key inputs include antibiotic use 60 days. Scores guide administering empiric broad-spectrum antimicrobial regimens, infectious source control, and isolation protocols. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Predicts risk for community-acquired pneumonia due to drug-resistant pathogens (CAP-DRP). Helps determine when broad-spectrum antibiotics should be used to ensure effective treatment while avoiding unnecessary antibiotic resistance.

Clinical Indication

The Drug Resistance in Pneumonia (DRIP) Score is indicated for bedside clinical practice to support Predicts risk for community-acquired pneumonia due to drug-resistant pathogens (CAP-DRP). Helps determine when broad-spectrum antibiotics should be used to ensure effective treatment while avoiding unnecessary antibiotic resistance.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with suspected sepsis, meningitis, pneumonia, COVID-19, opportunistic infections, or fever of unknown origin. Clinical application is indicated across Infectious disease services, septic shock bays, febrile illness clinics, and isolation units.

Limitations & Contraindications

Timely administration of empiric antibiotic therapy in suspected septic shock must never be delayed for score tabulation.

Clinical Pearls & Action Plan

Blood and site-specific microbiological cultures should be secured prior to administering broad-spectrum antimicrobials. Guideline pearl: At threshold ≥4 points: Sensitivity 0.82, Specificity 0.81, PPV 0.68, NPV 0.90..

Formula & Variables:

Major risk factors (2 points each): Antibiotic use within 60 days, Long-term care facility residence, Tube feeding, Prior drug-resistant infection. Minor risk factors (1 point each): Chronic pulmonary disease, Hospitalization within 60 days, Poor functional status, MRSA colonization, Wound care, Gastric acid suppression. Total: 0-14 points.

Input Parameters

NameTypeRequiredDescription
antibiotic_use_60_daysstringYesAntibiotic use within 60 days (Major risk factor)
long_term_care_facilitystringYesResidence in a long-term-care facility (Major risk factor)
tube_feedingstringYesTube feeding (Major risk factor)
prior_drug_resistant_infectionstringYesPrior infection with a drug-resistant pathogen (Major risk factor)
chronic_pulmonary_diseasestringYesChronic pulmonary disease (Minor risk factor)
hospitalization_60_daysstringYesPrior hospitalization within 60 days (Minor risk factor)
poor_functional_statusstringYesPoor functional status (Minor risk factor)
mrsa_colonizationstringYesMRSA colonization (Minor risk factor)
wound_carestringYesWound care (Minor risk factor)
gastric_acid_suppressionstringYesGastric acid suppression (Minor risk factor)

Score Interpretation & Guidance

RangeStageDescription
0–3Low RiskLow risk of drug-resistant pneumonia
4–14High RiskHigh risk of drug-resistant pneumonia

Evidence-Based References (EBM)

  • Webb BJ, Dascomb K, Stenehjem E, Dean N. Derivation and multicenter validation of the drug resistance in pneumonia clinical prediction score. Antimicrob Agents Chemother. 2016;60(5):2652-63. doi: 10.1128/AAC.03071-15.DOI: 10.1128/AAC.03071-15
  • Attridge RT, Frei CR, Restrepo MI, et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J. 2011;38(4):878-87. doi: 10.1183/09031936.00141110.DOI: 10.1183/09031936.00141110
  • Webb BJ, Dangerfield B, Pasha JS, et al. Guideline-concordant antibiotic therapy and clinical outcomes in healthcare-associated pneumonia. Respir Med. 2012;106(11):1606-12. doi: 10.1016/j.rmed.2012.08.010.DOI: 10.1016/j.rmed.2012.08.010

Related calculators